"We have a business that's growing substantially," CEO Raul Rodriguez said in an interview with CNBC's Brian Sullivan. "[We] grew 30% on average for four years, and this year, about 50% … adding new products, growing those products, financially disciplined, so that we are profitable."The stock has jumped about 50% in just the last three months, earning it a spot on CNBC's list of top performing stocks of companies based in the City by the Bay. To find the stocks, CNBC screened for names based in the area th ...

Core Viewpoint - NLS Pharmaceutics Ltd. is undergoing a significant transition involving a reverse stock split and a merger with Kadimastem Ltd. to enhance its market position and expand its capabilities in developing therapies for rare and complex central nervous system disorders [1][2][3] Group 1: Reverse Stock Split - A reverse stock split is scheduled for October 31, 2025, consolidating every 10 shares of NLSP into 1 share [2] - The current stock price is $0.74, reflecting a recent decrease of 29.52% [2] - The new CUSIP number for shares post-merger and reverse split will be H5835A109 [3] Group 2: Merger with Kadimastem Ltd. - The merger with Kadimastem Ltd. will result in a name change to NewcelX Ltd. and a new symbol "NCEL" on the Nasdaq Capital Market [2] - This merger aims to expand NLS Pharmaceutics' capabilities in its specialized field [3] Group 3: Market Performance - NLSP's stock has fluctuated between a low of $0.74 and a high of $0.94 today, with a yearly peak of $4.74 [3] - The company's market capitalization is approximately $2.34 million, with a trading volume of 1,409,410 shares [3]

TRENDING: You Don't Have To Dig Far To Cash In On Rare EarthsGuardant Health (GH) stock rocketed Thursday on an impressive beat-and-raise earnings report that included 40% volume growth from its oncology division.That 40% volume growth for oncology tests was a "wow," William Blair analyst Andrew Brackmann said in a report. The company's suite of liquid biopsy tests, including Guardant360, use genomic profiling to determine the drivers of a patient's cancer. This helps doctors select the right, targeted trea ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has a ROIC of -14.38% and a WACC of 13.83%, resulting in a negative ROIC to WACC ratio of -1.04.Comparatively, Black Diamond Therapeutics, Inc. (BDTX) showcases the most efficient capital use among peers with a ROIC of 2.99% and a WACC of 16.85%, leading to a ROIC to WACC ratio of 0.18.Phathom Pharmaceuticals, Inc. (PHAT) exhibits the most severe inefficiency in capital use with a ROIC of -149.31% against a WACC of 8.60%, resulting in a ROIC to WACC ratio of -17.3 ...

Core Insights - CorMedix Inc. is focused on developing therapeutic products for infectious and inflammatory diseases, with its flagship product, DefenCath/Neutrolin, aimed at reducing catheter-related infections and thrombosis [1] Price Target and Analyst Sentiment - The consensus price target for CorMedix has increased from $19.5 to $22 over the past year, indicating growing optimism among analysts [2] - RBC Capital analyst Gregory Renza has set a more conservative price target of $9, reflecting a cautious outlook [2] Strategic Acquisition - The acquisition of Melinta Therapeutics diversifies CorMedix's portfolio and raises its 2025 revenue guidance to at least $375 million, reducing reliance on a single product [3] - DefenCath remains the primary revenue driver, but the addition of Melinta's drugs offers further growth opportunities [3] Financial Performance - CorMedix's preliminary third-quarter results for 2025 show unaudited pro forma net revenue exceeding $125 million, with DefenCath generating over $85 million [4] - The company has raised its full-year 2025 net revenue guidance to at least $375 million and anticipates achieving approximately $30 million in operating synergy by the end of 2025 [4] Product Adoption and Market Position - DefenCath is experiencing strong adoption as the only FDA-approved antimicrobial catheter-lock solution, with rapid uptake in dialysis clinics [5] - Favorable policies, such as Medicare's TDAPA, support full reimbursement for outpatient treatments, enhancing CorMedix's near-term revenue potential [5]

Core Insights - Abeona Therapeutics has received a permanent HCPCS J-code for its gene therapy ZEVASKYN, which will enhance reimbursement processes and patient access starting January 1, 2026 [1][2] Company Overview - Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [7] - ZEVASKYN (prademagene zamikeracel) is the first and only autologous cell sheet-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [3][4] Product Details - ZEVASKYN is designed to treat wounds in adult and pediatric patients suffering from RDEB, a severe skin disease caused by defects in the COL7A1 gene [3][4] - The therapy involves inserting the correct COL7A1 gene into a patient's skin cells ex vivo, leading to the production of functional type VII collagen [3] - Clinical results indicate that ZEVASKYN provides meaningful wound healing and pain reduction with a single application [3] Regulatory and Market Impact - The assignment of a unique J-code by CMS is expected to simplify claims and reimbursement processing, thereby supporting hospital adoption and patient access for ZEVASKYN [2] - J-codes are crucial for identifying non-orally administered medications in healthcare settings, streamlining medical billing and reimbursement processes [2]

Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and BioNTech (NASDAQ:BNTX) announced that the Health Sciences Authority/HSA of Singapore approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1; COVID-19 Vaccine, mRNA). The approval makes Singapore the first country in Southeast Asia to fully approve the latest COVID-19 vaccine for use in individuals 6 months of age and older. The LP.8.1 sublineage was chosen based ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Equinox Gold (EQX) engages in the acquisition, exploration and development of mineral deposits. The Zacks Consensus Estimate for its current year earnings has been revised almost 26.5% downward over the last 60 days.Golden Entertainment (GDEN)  is a diverse gaming company which offers casino, distribute gaming and lottery services. The Zacks Consensus Estimate for its current year earnings has been revised 16.2% downward over the last ...

Tori Spelling shares her and her family’s journey with eczema and seborrheic dermatitis to encourage others to take control of their skin healthZORYVE® (roflumilast) is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined – eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovatio ...

Bristol-Myers Squibb Company (NYSE:BMY) Q3 2025 Earnings Call October 30, 2025 08:00 AM ET Company ParticipantsAkash Tewari - Global Head of Biopharmaceutical ResearchChris Schott - Managing DirectorChuck Triano - SVP and Head of Investor RelationsMohit Bansal - Managing Director and Co-Head of Therapeutics ResearchCristian Massacesi - Chief Medical Officer and Head of Global Drug DevelopmentChris Boerner - Board Chair and CEOAdam Lenkowsky - Chief Commercialization OfficerCarter Gould - Biopharma Equity Re ...